Form D · Pharmaceuticals
LEXICON PHARMACEUTICALS, INC.
The Woodlands, TX · CIK 0001062822
Offering snapshot reported Feb 17, 2026 · SEC filing
- Reported sold
- $55.7M Offering amount: $59.2M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 2, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 17, 2026 | Initial | $55,668,255 | No comparison | 1 | SEC filing |
| Jun 20, 2023 | Initial | $72,215,130 | No comparison | 1 | SEC filing |
| Aug 3, 2022 | Initial | $42,891,000 | No comparison | 2 | SEC filing |
| Mar 24, 2017 | Initial | $10,506,500 | No comparison | 16 | SEC filing |
| Dec 12, 2014 | Initial | $4,662,780 | No comparison | 16 | SEC filing |
| Dec 8, 2014 | Initial | $150,000,000 | No comparison | 1 | SEC filing |
| Aug 7, 2012 | Initial | $35,000,000 | No comparison | 16 | SEC filing |
| Mar 31, 2010 | Initial | $75,035,737 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-573732
Total Offering Amount includes gross proceeds from the private placement of common stock and the issuance of convertible preferred securities, including a partially exercised option to purchase additional convertible preferred securities.
Source: Form D, filed Feb 17, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kristen L. Alexander | Executive |
| Phillipe J. Amouyal | Director |
| Philippe J. Amouyal | Director |
| Samuel Barker | Director |
| Philip M Brown | Executive |
| Ivan H. Cheung | Director |
| Lonnel Coats | Director, Executive |
| Scott Coiante | Executive |
| Brian T. Crum | Executive |
| Raymond Debbane | Director |
| Lisa De Francesco | Executive |
| Mike Exton | Director, Executive |
| Suma Gopinathan | Executive |
| Craig B. Granowitz | Executive |
| Kenneth B. Kassler Taub | Executive |
| Pablo Lapuerta | Executive |
| Robert J. Lefkowitz | Director |
| Alan J. Main | Executive |
| Rachel Martens | Executive |
| Wendy E. Mc Dermott | Executive |
| Alan S. Nies | Director |
| John Northcott | Executive |
| Frank P. Palantoni | Director |
| Arthur T. Sands | Director, Executive |
| Alexander Santini | Executive |
| Kiernan A. Seth | Executive |
| Christopher Sobecki | Director |
| Diane E. Sullivan | Director |
| Judith L. Swain | Director |
| James F. Tessmer | Executive |
| Steven A Tragash | Executive |
| Praveen Tyle | Executive |
| Jeffrey L. Wade | Executive |
| Brian P. Zambrowicz | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2445 Technology Forest Blvd., 11th Floor
The Woodlands, TX, 77381
Phone: 281-863-3000
The Woodlands, TX, 77381
Phone: 281-863-3000